Bristol Myers' pipeline milestones key to growth, analysts say
BMY•Bristol Myers Squibb raised its full-year revenue forecast but lowered its 2026 earnings per share projection. Analysts said upcoming study updates for several medicines could provide potential growth drivers.
1. Pipeline milestones ahead
Analysts said upcoming study updates could provide growth opportunities for Bristol Myers Squibb, while citing concerns about the launch of schizophrenia drug Cobenfy and mixed trial results for admilparant. Updates for Cobenfy, blood thinner milvexian, Sotyktu and cancer therapies CELMoDs are expected through early 2027.
2. Analyst views differ
Morgan Stanley called data for milvexian in atrial fibrillation the most important upcoming catalyst. Truist Securities and Jefferies rated the stock buy, while Morgan Stanley rated it underweight and TD Cowen rated it hold; 30 analysts rate the stock buy on average, with a median price target of $64.50.
